Inclusion Criteria:

          -  Patients must have histologic evidence of relapsed or refractory B-cell ALL

          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of
             2 or less

          -  Philadelphia chromosome positive (Ph+) patients must be refractory to or intolerant of
             standard tyrosine kinase inhibitor therapy

          -  Patients must be able to consume oral medication

          -  Patients must have recovered to =< grade 1 or stabilized from the toxic effects of any
             prior chemotherapy (except alopecia)

          -  Creatinine clearance (CrCL) >= 60 mL/min/1.73 m^2 calculated by Cockcroft-Gault

          -  Total bilirubin < 1.5 x upper limit of normal (ULN)

          -  Negative serum or urine pregnancy test for women with child-bearing potential

          -  Patients must be able to sign consent and be willing and able to comply with scheduled
             visits, treatment plan, procedures, and laboratory testing

        Exclusion Criteria:

          -  Patients must not have evidence of active central nervous system (CNS) disease

          -  Patients must not be receiving any chemotherapy agents (except hydroxyurea);
             intrathecal methotrexate and intrathecal cytarabine are permissible

          -  Patients must not be receiving growth factors (granulocyte colony-stimulating factor
             [G-CSF], granulocyte-macrophage colony-stimulating factor [GM-CSF]), except for
             erythropoietin

          -  Patient must not have a concurrent active malignancy for which they are receiving
             treatment.

          -  Patients with other severe concurrent disease which in the judgment of the
             investigator would make the patient inappropriate for entry into this study are
             ineligible

          -  Patients must not have received any investigational agents within 30 days of study
             entry unless they have exceeded 5 terminal half-lives of the previous study drug used
             for treatment

          -  Patients must not be pregnant or breastfeeding; pregnancy tests must be obtained for
             all females of child-bearing potential within 10 days prior to enrollment; males or
             women of childbearing potential may not participate unless they have agreed to use an
             effective contraceptive method (defined as hormonal contraceptives, intrauterine
             devices, surgical contraceptives, or condoms)

          -  Patients who have uncontrolled infection are not eligible; patients must have any
             active infections under control; fungal disease must have been adequately treated for
             at least 2 weeks before study entry; subjects with bacteremia must have documented
             negative blood cultures prior to study entry

          -  Patients who are candidates for allogeneic transplantation, have a suitable donor, and
             are willing to undergo transplantation

          -  Patients who are eligible for and willing to receive treatment with tisagenlecleucel.